Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions

Abstract

Intra-arterial therapies (IATs) play a pivotal role in the management of patients with primary and secondary liver malignancies. The unique advantages of these treatments are their ability to selectively deliver a high dose of anticancer treatment while preserving healthy liver tissue. The proven efficacy of these catheter-based locoregional therapies in a highly systemic chemoresistant cancer such as hepatocellular carcinoma (HCC), along with the minimally invasive nature of these treatments, quickly yielded wide acceptance in the medical community and revolutionized the field of Interventional Oncology. In this article, we describe the clinical rationale and background of catheter-based IATs. We provide an overview of clinical achievements of these treatments alone and in combination with sorafenib in patients with HCC.

Radiation dose reduction capabilities of a new C-arm system with optimized hard- and software

“…All cases were presented at our multidisciplinary tumor board and interdisciplinary consensus for the indication and treatment modality was reached. All interventions were conducted by radiologists with more than 5 years of experience in interventional oncology, following a standardized approach [18]. Drug-eluting Bead chemoembolization (DEB-TACE) was performed in all cases.…”

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

“…Bland embolization with temporary agent, e.g., Gelfoam. 147 Deliver higher doses of cytotoxic chemotherapy and potentiate therapeutic action, while decreasing the systemic effects of the chemotherapy agent 148,149 Highest level of evidence in treatment of HCC and incorporated in BCLC Specialized microspheres are loaded with antitumor drugs, most commonly doxorubicin or irinotecan, which are then delivered transarterially to the tumor.…”

Heterogeneity analysis of triphasic CT scan perfusion parameters in differential diagnosis of hepatocellular carcinoma and hemangioma

“…Of the early detected HCC cases, up to 90% of the patients could be cured under the best circumstances. [ 5 , 6 ] According to the European Association for the Study of Liver Diseases 2000 Conference [ 7 ] and American Association for the study of Liver Diseases guidelines, [ 8 ] diagnosis of HCC based on conventional enhancement computed tomography (CT) relies on the observation of arterial enhancement, which is followed by the contrast washout in the venous phase. [ 9 ] However, the HCC lesions <20 mm are always difficult to diagnose due to the specific vascularization pattern and the complicated liver texture with cirrhotic background.…”